WO2011060944A8 - Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters - Google Patents
Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters Download PDFInfo
- Publication number
- WO2011060944A8 WO2011060944A8 PCT/EP2010/007024 EP2010007024W WO2011060944A8 WO 2011060944 A8 WO2011060944 A8 WO 2011060944A8 EP 2010007024 W EP2010007024 W EP 2010007024W WO 2011060944 A8 WO2011060944 A8 WO 2011060944A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fatty acid
- polyunsaturated fatty
- active pharmaceutical
- acid esters
- pharmaceutical ingredient
- Prior art date
Links
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 title abstract 3
- 239000008186 active pharmaceutical agent Substances 0.000 title abstract 2
- 239000002775 capsule Substances 0.000 title abstract 2
- 150000002148 esters Chemical class 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 125000005907 alkyl ester group Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Botany (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Pharmaceutical composition in the form of a capsule which contains alkyl esters of polyunsaturated fatty acid (PUFA) and active pharmaceutical ingredients for the treatment and/or prevention of cardiovascular diseases and/or inflammatory processes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200931026 | 2009-11-20 | ||
ES200931026A ES2363964B1 (en) | 2009-11-20 | 2009-11-20 | CAPSULES OF PHARMACEUTICAL ACTIVE PRINCIPLES AND ESTERS OF POLYINSATURATED FATTY ACIDS. |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2011060944A2 WO2011060944A2 (en) | 2011-05-26 |
WO2011060944A8 true WO2011060944A8 (en) | 2011-10-27 |
WO2011060944A3 WO2011060944A3 (en) | 2012-05-03 |
Family
ID=43498493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/007024 WO2011060944A2 (en) | 2009-11-20 | 2010-11-19 | Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR079429A1 (en) |
ES (1) | ES2363964B1 (en) |
TW (1) | TW201141470A (en) |
WO (1) | WO2011060944A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2385240B1 (en) * | 2010-07-26 | 2013-09-23 | Gp-Pharm, S.A. | CAPSULES OF ACTIVE PHARMACEUTICAL PRINCIPLES AND POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF PROSTATE DISEASES. |
ITMI20112221A1 (en) * | 2011-12-05 | 2013-06-06 | Altergon Sa | STABLE FORMULATIONS IN JELLY CAPSULES SPRINGS OF PIASTRINICAL ANTI-AGGREGATES, OMEGA-3 FATTY ACIDS AND AMYLOSUS |
EP2836206A4 (en) * | 2012-04-10 | 2015-11-04 | Rubicon Res Private Ltd | Controlled release pharmaceutical formulations of direct thrombin inhibitors |
WO2014007779A1 (en) * | 2012-07-06 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Orally-disintegrating formulations of dexketoprofen |
WO2014007780A1 (en) * | 2012-07-06 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Orally-disintegrating formulations of dexketoprofen |
CN103626689B (en) * | 2012-08-24 | 2016-03-09 | 上海医药工业研究院 | A kind of preparation method of intermediate of Eliquis |
WO2015195990A1 (en) * | 2014-06-20 | 2015-12-23 | Banner Life Sciences Llc | Liquid-filled immediate release soft gelatin capsules |
CN106620707B (en) * | 2017-03-14 | 2019-06-07 | 牡丹江医学院 | A kind of pharmaceutical composition and its preparation method and application preventing and treating myocardial ischemia |
WO2019178444A1 (en) | 2018-03-15 | 2019-09-19 | R.P. Scherer Technologies, Llc | Enteric softgel capsules |
CN114869857B (en) * | 2022-05-12 | 2023-04-04 | 郑州大学第一附属医院 | Argatroban particles, preparation and preparation method thereof |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5312473B1 (en) | 1971-05-24 | 1978-05-01 | ||
PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
JPS5920230A (en) | 1982-07-19 | 1984-02-01 | チバ−ガイギ−・アクチエンゲゼルシヤフト | Drug containing piruprophen |
JPS60100516A (en) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | Preparation of sustained release microcapsule |
US4609675A (en) | 1984-08-17 | 1986-09-02 | The Upjohn Company | Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing |
GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
US4857552A (en) | 1988-06-08 | 1989-08-15 | E. I. Du Pont De Nemours And Co. | Stable pharmaceutical composition |
US4954346A (en) | 1988-06-08 | 1990-09-04 | Ciba-Geigy Corporation | Orally administrable nifedipine solution in a solid light resistant dosage form |
US5035896A (en) | 1988-06-15 | 1991-07-30 | Warner-Lambert Company | Water insoluble drugs coated by coacervated fish gelatin |
FR2660555B1 (en) | 1990-04-06 | 1994-09-16 | Rhone Poulenc Sante | KETOPROFEN OIL CAPSULE. |
AU639988B2 (en) | 1990-04-11 | 1993-08-12 | Pharmacia & Upjohn Company | Taste masking of ibuprofen by fluid bed coating |
CA2039742A1 (en) | 1990-04-23 | 1991-10-24 | Andrew B. Dennis | Tablet composition and method for problem pharmaceutical materials |
CH683149A5 (en) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Process for the preparation of microspheres of a biodegradable polymeric material. |
ZA945944B (en) | 1993-08-13 | 1996-02-08 | Eurand America Inc | Procedure for encapsulating nsaids |
TW358812B (en) | 1994-03-15 | 1999-05-21 | Senju Pharma Co | Method for stabilizing pranoprofen and a composition and a package thereof |
US5447729A (en) | 1994-04-07 | 1995-09-05 | Pharmavene, Inc. | Multilamellar drug delivery systems |
GB2290965A (en) | 1994-07-11 | 1996-01-17 | Therapicon Srl | Multiple layer capsules for drugs |
EP0839029A1 (en) | 1995-07-20 | 1998-05-06 | PHARMACIA & UPJOHN COMPANY | Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules |
WO1997033568A1 (en) | 1996-03-12 | 1997-09-18 | Novartis Ag | Filled gelatin capsules having a reduced degree of cross-linking |
US6251426B1 (en) | 1999-09-02 | 2001-06-26 | Banner Pharmacaps, Inc. | Ibuprofen-containing softgels |
CN1174741C (en) | 1999-09-21 | 2004-11-10 | Rtp药品公司 | Surface modified particulate compositions of biologically active substances |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
DE10026699A1 (en) | 2000-05-30 | 2001-12-06 | Basf Ag | Formulation based on heparin, glycosaminoglycan or heparinoid and use of the formulation and the formulation base |
PT1321140E (en) | 2000-08-25 | 2005-06-30 | Kowa Co | IBUPRHENE SOLUTIONS FOR FILLING CAPSULES AND CAPSULA PREPARATIONS |
US6387400B1 (en) | 2000-08-29 | 2002-05-14 | R.P. Scherer Technologies, Inc. | Process for preparing pharmaceutical compositions for use with soft gelatin formulations |
TWI277414B (en) | 2001-01-12 | 2007-04-01 | Baxter Int | Esmolol formulation |
US6673944B2 (en) | 2001-02-28 | 2004-01-06 | Taro Pharmaceutical Industries, Ltd. | Preparation of warfarin sodium from warfarin acid |
ITMI20020731A1 (en) * | 2002-04-08 | 2003-10-08 | Ibsa Inst Biochimique Sa | PHARMACEUTICAL COMPOSITIONS FOR ACETYLSALICYLIC ACID AND OMEGA-3 OILS |
ITFI20020144A1 (en) | 2002-08-01 | 2004-02-02 | Menarini Farma Ind | STABILIZED TOPICAL FORMULATIONS CONTAINING KETOPROFENE. |
US20040115226A1 (en) | 2002-12-12 | 2004-06-17 | Wenji Li | Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same |
GB0325603D0 (en) | 2003-11-03 | 2003-12-10 | Sandoz Ag | Organic compounds |
JP2007512372A (en) | 2003-11-25 | 2007-05-17 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | Carvedilol salts, corresponding compositions, delivery and / or treatment methods |
WO2006135415A2 (en) | 2004-09-08 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Micelles and nanoemulsions for preventative and reactive treatment of atherosclerosis |
DE602005018387D1 (en) | 2004-10-06 | 2010-01-28 | Eisai R&D Man Co Ltd | MEDICAL COMPOSITION, PROCESS FOR YOUR HDI-HYDROPYRIDINE COMPOUND IN A MEDICAL COMPOSITION |
ES2255426B1 (en) * | 2004-10-19 | 2007-08-16 | Gp Pharm, S.A. | PHARMACEUTICAL FORMULATION THAT INCLUDES MICROCAPSULES OF STATINS SUSPENDED IN ESTER ALKYLS OF POLYINSATURATED FATTY ACIDS (PUFA). |
EP1846040A2 (en) | 2005-01-28 | 2007-10-24 | Collegium Pharmaceutical, Inc. | Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents |
DK1688129T3 (en) | 2005-02-02 | 2015-10-05 | Omega Pharma Innovation & Developement N V | New therapeutic formulation |
WO2006102476A2 (en) * | 2005-03-21 | 2006-09-28 | Vicus Therapeutics Spe 1, Llc | Compositions and methods for ameliorating cachexia |
AU2006275784A1 (en) | 2005-07-28 | 2007-02-08 | Reliant Pharmaceuticals, Inc. | Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof |
WO2007103557A2 (en) * | 2006-03-09 | 2007-09-13 | Reliant Pharmaceuticals, Inc. | Coating capsules with active pharmaceutical ingredients |
KR100913791B1 (en) | 2006-07-21 | 2009-08-26 | 한미약품 주식회사 | S---amlodipine camsylate or hydrate thereof and pharmaceutical composition containing same |
WO2008062435A2 (en) | 2006-08-15 | 2008-05-29 | Alkem Laboratories Ltd. | Stabilised dosage forms of amlodipine besylate |
EP1894561A1 (en) | 2006-08-30 | 2008-03-05 | Dr. Reddy's Laboratories Ltd. | Dipyridamole pharmaceutical compositions |
DE602007012497D1 (en) | 2006-09-25 | 2011-03-31 | Adamed Sp Zoo | New clopidogrel salt and its crystalline forms |
JP2010506841A (en) | 2006-10-13 | 2010-03-04 | リライアント・ファーマシューティカルズ・インコーポレイテッド | Treatment with antiarrhythmic drugs and omega-3 fatty acids and combinations thereof |
US7749537B2 (en) | 2006-12-04 | 2010-07-06 | Scolr Pharma, Inc. | Method of forming a tablet |
WO2008070950A1 (en) | 2006-12-13 | 2008-06-19 | Laboratoires Mauves Inc. | Pharmaceutical solution formulations for encapsulation into gelatin capsules or other dosage forms |
KR20080055356A (en) | 2006-12-15 | 2008-06-19 | 에스케이케미칼주식회사 | Inclusion complex of clopidogrel and beta-cyclodextrin |
JP2010515773A (en) | 2007-01-16 | 2010-05-13 | リライアント・ファーマシューティカルズ・インコーポレイテッド | Treatment with non-steroidal anti-inflammatory drugs and omega-3 fatty acids and combination products thereof |
WO2008122994A2 (en) | 2007-04-09 | 2008-10-16 | Usv Limited | Stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof |
US20100239665A1 (en) * | 2007-05-01 | 2010-09-23 | Ivan Coulter | Pharmaceutical nimodipine compositions |
-
2009
- 2009-11-20 ES ES200931026A patent/ES2363964B1/en not_active Expired - Fee Related
-
2010
- 2010-11-18 AR ARP100104271A patent/AR079429A1/en unknown
- 2010-11-19 TW TW099139977A patent/TW201141470A/en unknown
- 2010-11-19 WO PCT/EP2010/007024 patent/WO2011060944A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
ES2363964B1 (en) | 2012-08-22 |
WO2011060944A2 (en) | 2011-05-26 |
ES2363964A1 (en) | 2011-08-22 |
WO2011060944A3 (en) | 2012-05-03 |
AR079429A1 (en) | 2012-01-25 |
TW201141470A (en) | 2011-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011060945A3 (en) | Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases | |
WO2011060944A8 (en) | Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters | |
WO2012013331A3 (en) | Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases | |
PH12016500216A1 (en) | Stable pharmaceutical composition and methods of using same | |
WO2009091538A3 (en) | Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia | |
NZ734905A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
NZ618734A (en) | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | |
IL210233A (en) | Omega-3 fatty acid formulations containing epa and dha and no active ingredients other than omega-3 fatty acids | |
ZA201202263B (en) | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same | |
NZ595204A (en) | Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof | |
NZ600721A (en) | Capsule formulation | |
MY165048A (en) | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | |
GB2459809A (en) | Fatty acid formulations and methods of use thereof | |
MX2016004487A (en) | Enteric soft capsules comprising polyunsaturated fatty acids. | |
WO2010129565A3 (en) | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae | |
EP2506848A4 (en) | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof | |
WO2011051354A3 (en) | Transdermal pharmaceutical compositions comprising active agents | |
PL2575787T3 (en) | Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation | |
WO2011097276A8 (en) | Methods and compositions for treating arthritis with docosahexaenoic acid | |
GEP20125464B (en) | Dha esters and use thereof in treatment and prevention of cardiovascular disease | |
WO2007090408A3 (en) | Coated tablets, their methods of preparation, and related uses | |
WO2010136900A3 (en) | Methods of using krill oil to treat risk factors for metabolic disorders and obesity | |
EP2560633B8 (en) | Intravenous omega-3 fatty acid compositions & method of use | |
WO2013136183A3 (en) | Oxidixable fatty acid composition delivery form | |
MX2009004339A (en) | Fatty acid alcohols. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10788004 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10788004 Country of ref document: EP Kind code of ref document: A2 |